It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Pel exopolysaccharide biosynthetic loci are phylogenetically widespread biofilm matrix determinants in bacteria. In Pseudomonas aeruginosa, Pel is crucial for cell-to-cell interactions and reducing susceptibility to antibiotic and mucolytic treatments. While genes encoding glycoside hydrolases have long been linked to biofilm exopolysaccharide biosynthesis, their physiological role in biofilm development is unclear. Here we demonstrate that the glycoside hydrolase activity of P. aeruginosa PelA decreases adherent biofilm biomass and is responsible for generating the low molecular weight secreted form of the Pel exopolysaccharide. We show that the generation of secreted Pel contributes to the biomechanical properties of the biofilm and decreases the virulence of P. aeruginosa in Caenorhabditis elegans and Drosophila melanogaster. Our results reveal that glycoside hydrolases found in exopolysaccharide biosynthetic systems can help shape the soft matter attributes of a biofilm and propose that secreted matrix components be referred to as matrix associated to better reflect their influence.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details











1 The Hospital for Sick Children, Program in Molecular Medicine, Toronto, Canada (GRID:grid.42327.30) (ISNI:0000 0004 0473 9646); University of Toronto, Department of Biochemistry, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938)
2 The Hospital for Sick Children, Program in Molecular Medicine, Toronto, Canada (GRID:grid.42327.30) (ISNI:0000 0004 0473 9646); University of Toronto, Department of Biochemistry, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938); Faculté de Médecine Université de Montréal, Département de Microbiologie, Infectiologie, et Immunologie, Montréal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2292 3357)
3 University of Washington, Department of Microbiology, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657); Washington University, Department of Chemistry, St. Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002)
4 University of Washington, Department of Microbiology, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657)
5 University of Toronto, Department of Molecular Genetics, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938)
6 The Hospital for Sick Children, Program in Developmental and Stem Cell Biology, Toronto, Canada (GRID:grid.42327.30) (ISNI:0000 0004 0473 9646)
7 The Ohio State University, Department of Microbial Infection and Immunity, Columbus, USA (GRID:grid.261331.4) (ISNI:0000 0001 2285 7943); VA-MD College of Veterinary Medicine, Department of Biomedical Sciences and Pathobiology, Virginia Tech, USA (GRID:grid.470073.7) (ISNI:0000 0001 2178 7701)
8 University of Toronto, Department of Materials Science and Engineering, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938)
9 University of Calgary, Department of Biological Sciences, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697)
10 University of Washington, Department of Microbiology, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657); BioVectra Inc. 11 Aviation, Charlottetown, Canada (GRID:grid.34477.33)
11 McGill University, Department of Microbiology and Immunology, Faculty of Medicine, Montreal, Canada (GRID:grid.14709.3b) (ISNI:0000 0004 1936 8649); Research Institute of the McGill University Health Centre, Infectious Disease and Immunity in Global Health, Montreal, Canada (GRID:grid.63984.30) (ISNI:0000 0000 9064 4811); McGill Interdisciplinary Initiative in Infection and Immunity, Montreal, Canada (GRID:grid.63984.30)
12 The Ohio State University, Department of Microbial Infection and Immunity, Columbus, USA (GRID:grid.261331.4) (ISNI:0000 0001 2285 7943); The Ohio State University, Department of Orthopedics, Columbus, USA (GRID:grid.261331.4) (ISNI:0000 0001 2285 7943); University of Southampton, National Biofilm Innovation Centre (NBIC) and National Centre for Advanced Tribology at Southampton (nCATS), Southampton, UK (GRID:grid.5491.9) (ISNI:0000 0004 1936 9297); The Ohio State University, Department of Microbiology, Columbus, USA (GRID:grid.261331.4) (ISNI:0000 0001 2285 7943)
13 University of Toronto, Department of Molecular Genetics, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938); The Hospital for Sick Children, Program in Developmental and Stem Cell Biology, Toronto, Canada (GRID:grid.42327.30) (ISNI:0000 0004 0473 9646)
14 The Ohio State University, Department of Microbial Infection and Immunity, Columbus, USA (GRID:grid.261331.4) (ISNI:0000 0001 2285 7943); The Ohio State University, Department of Microbiology, Columbus, USA (GRID:grid.261331.4) (ISNI:0000 0001 2285 7943)